Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 avr. 2024 08h00 HE | Source: SIRPant Immunotherapeutics, Inc.

SIRPant Immunotherapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium

HUMMELSTOWN, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based...
12 mars 2024 08h00 HE | Source: SIRPant Immunotherapeutics, Inc.

SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

HUMMELSTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based...
22 janv. 2024 08h00 HE | Source: SIRPant Immunotherapeutics, Inc.

SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.

HUMMELSTOWN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...
12 déc. 2023 08h00 HE | Source: SIRPant Immunotherapeutics, Inc.

SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors

HUMMELSTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...
15 nov. 2023 09h00 HE | Source: SIRPant Immunotherapeutics, Inc.

SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma

HUMMELSTOWN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...
27 sept. 2023 09h00 HE | Source: Sirpant Immunotherapeutics, Inc.

SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting

HUMMELSTOWN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...